EP 78: Your Guide to Lipoprotein(a) with Dr. Salim S Virani
EP 78: Your Guide to Lipoprotein(a) with Dr. Salim S Virani

Average (ratings)
No ratings
 
  Your rating

This week’s Parallax episode is focusing on the latest science and questions surrounding one of the conundrums of cardiovascular science: Lipoprotein(a).
Dr. Ankur Kalra invites Dr Salim S Virani to help simplify the concept of Lp(a) with answering key questions about its measurement and its place in practice and prevention.
 
Dr Virani is a Professor at Baylor College of Medicine, Director of the Cardiovascular Disease Fellowship Program and Vice Provost of Research at Aga Khan University from early next year.
 
Lp(a) was first described in 1963. Since then, many epidemiologic studies have noted association of high Lp(a) levels with elevated risk of cardiovascular disease, however, the role of this particle remained a conundrum (Kamstrup, 2017). New data from the development of novel drugs are offering strong evidence on the causality between Lp(a) and ASCVD and AVS (Kronenber et al. 2022).
Dr Virani, one of the authors of the new European Atherosclerosis Society consensus statement on Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis, summarises the key concepts, shares his advice on clinical practice and talks about emerging therapies.
 
What is Lp(a) and what are the main associations? In what patient population should we lower LP(a)? What do you tell patients about Lp(a) testing and how easy it is to get it tested?

Questions and comments can be sent to “podcast@radcliffe-group.com” and may be answered by Ankur in the next episode.
Guest: @virani_md, host: @AnkurKalraMD and produced by: @RadcliffeCARDIO.


Read MoreRead Less
Share
Up Next
Guest Episode: Exploring Art & Advancement Within Medicine
EP79 • Oct 31, 2022 • 33m
This week's Parallax is hosting a guest episode recorded for Internal Medicine & Beyond. Tune in to this new podcast from Dr Varun Aitharaju.

Exploring Art & Advancement Within Medicine - A Conversation with an Interventional Cardiologist.
Read More
All Episodes
01: Conduction Abnormalities After TAVR/TAVI With Chad Kliger
EP01 • Apr 23, 2020 • 27m 44s
In our first episode, Ankur explains his vision for and inspiration to start ‘Parallax’, and speaks with Chad Kliger from Lenox Hill Hospital in New York about conduction abnormalities after transcatheter aortic valve replacement (TAVR/TAVI), a review article published in US Cardiology Review 13.1 Ankur and Chad look at conduction abnormalities after TAVR/TAVI with a focus on basic conduction system anatomy in relation to the aortic valve, the mechanism, incidence, predisposing factors for occurrence, impact on mortality and finally, proposed treatment algorithms for management. Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Read More
21: The “Interventional Intensivist” With Ann Gage
EP21 • Apr 23, 2020 • 32m 18s
We can count on our fingertips how many interventional intensivists exist in the US.



In this episode Ankur Kalra, MD meets with Dr Ann Gage, Cleveland Clinic’s first ‘interventional intensivist’. She discusses her unique skill set, what it means to be an interventionalist in the cath lab but also an expert in cardiovascular intensive care and advocates why such a unique skill set and critical care training are required in today’s modern medicine.



Listen to this engaging discussion between them on the challenges of being a woman in cardiovascular medicine today.



Submit your question to Ankur via: podcast@radciffe-group.com. Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Read More
Staging Of Aortic Valve Disease: A Novel Approach
EP20 • Apr 23, 2020 • 41m 53s
Dr Cavalcante meets with Ankur Kalra, MD to discuss his recent review published in US Cardiology Review 13.2; on a new aortic stenosis staging system that has important implications for clinical outcomes following aortic valve replacements to aid the treatment of aortic stenosis.



Listen to this, as well as an overview on his interesting childhood and his views on the future of cardiac imaging to treat TAVR.



Submit your question to Ankur via: podcast@radciffe-group.com. Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Read More
19: Women In Cardiology With Kendra Grubb
EP19 • Apr 23, 2020 • 41m 30s
The first female cardiac surgeon qualified in the 1960’s. Today there are only 4.5% women in cardiology and only 4% in thoracic surgery. Ankur Kalra meets with Dr Kendra Grubb, the first women to be trained at the University of Virginia, US, on cardiothoracic surgery and the 250th board certified women in thoracic surgery.



Her recent post on social media went viral. It was a photo of an all-women surgical team carrying out a complex structural heart procedure. It had over 100,000 views and was seen by people in over 75 different countries. It’s clear from this online reaction, that now is the time for women to be recognised for the work they are doing in medicine.



Listen to this engaging discussion between them on the challenges of being a woman in cardiovascular medicine today.



Submit your question to Ankur via: podcast@radciffe-group.com. Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Read More
18: The Year 2019 In Review With Sukh Nijjer
EP18 • Apr 23, 2020 • 1h 58m 55s
In our final episode of the year, Ankur has an long conversation with Sukh Nijjer from Imperial College London about the most impactful, exciting and controversial clinical trials of 2019. Sukh and Ankur also discuss how these trials might change practice in the future, and how practice patterns and decisions differ between the US and the UK. In light of an emerging trend of shared decision making between physicians of different specialities and patients with a vast amount of information at their fingertips, Sukh and Ankur examine what tools they use to reconcile the growing data from clinical trials.



Trials discussed in detail include those presented at the ACC in New Orleans: PARTNER 3 & Evolut Low Risk on TAVR/TAVI, and SAFARI & COAPT on radial vs femoral access; presented at the ESC in Paris: THEMIS and ISAR-REACT 5 on DAPT post-PCI, DAPA-HF on SGLT2i’s for heart failure, and COMPLETE on PCI of non-culprit lesions in STEMI; presented at TCT in San Francisco: TWILIGHT on DAPT post-PCI, and EXCEL at 5 years on PCI vs CABG in left main CAD; and finally, presented at AHA in Philadelphia: ISCHEMIA on medical vs invasive approaches in ischemic events. Submit your question to Ankur via: podcast@radciffe-group.com.



Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Read More
Rasha Al-Lamee On ORBITA, ISCHEMIA, Coronary Revascularisation
EP17 • Apr 23, 2020 • 38m 2s
Recorded before the American Heart Association (AHA) Scientific Sessions 2019, Ankur is joined by Rasha K Al-Lamee, Interventional Cardiologist at Imperial College Healthcare NHS Trust in London and Study Director of the Objective Randomised Blinded Investigation with Optimal Medical Therapy of Angioplasty in Stable Angina (ORBITA) trial. Rasha talks about how she got into academia, the significance of her end-of-training PhD, and what led to the genesis of ORBITA.



Ankur and Rasha also discuss the findings and unanswered questions of ORBITA, and how recent research in coronary revascularisation and stable ischemic heart disease has (or has not) changed their clinical practice. Finally, in anticipation of its presentation at AHA 2019, Rasha gives an overview of the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA). Submit your question to Ankur via: podcast@radciffe-group.com.



Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Read More